“On-Site Family Screening” in Fabry Disease: An Innovative Model for Identifying At-Risk Relatives
- 1Department of Nephrology, Mardin Training and Research Hospital, 47100 Mardin, Türkiye
- 2Department of Nephrology, Yalova Training and Research Hospital, 77200 Yalova, Türkiye
- 3Department of Medical Genetics, Multigen Genetic Diseases Diagnosis Center, 35535 İzmir, Türkiye
Abstract
Background: Fabry disease remains underdiagnosed despite the availability of effective therapies. Although cascade screening is recommended for identifying at-risk relatives, its implementation is often limited by practical and accessibility barriers, resulting in missed or delayed diagnoses. On-Site Family Screening (OSFS) was developed to overcome barriers to conventional cascade screening and improve the identification of previously undiagnosed relatives with Fabry disease. Therefore, this study aimed to implement and evaluate the diagnostic impact of an On-Site Family Screening approach for identifying previously undiagnosed individuals with Fabry disease within an extended family. Methods: Following the identification of the index case, at-risk relatives were systematically evaluated through on-site visits at their place of residence. Pedigree analysis was used to identify individuals at risk. Written informed consent was obtained from all participants prior to genetic testing, and molecular analysis of the GLA gene was performed. Of all at-risk relatives identified through pedigree analysis, ten at-risk individuals declined participation for personal reasons and were excluded from the analysis. Results: A total of 56 individuals were screened. Seventeen previously undiagnosed individuals with Fabry disease were identified, including 10 males and 7 females, corresponding to a diagnostic yield of 30.4%. The mean age at diagnosis was 22.94 years, with an age range from 45 days to 55 years. Notably, two affected male infants aged 45 and 60 days were detected before the development of overt disease manifestations. All affected individuals carried the same pathogenic GLA variant, consistent with familial X-linked inheritance. Conclusions: In this single extended pedigree, on-site family screening was feasible and facilitated the identification of previously undiagnosed relatives, including individuals at very young and presymptomatic stages. This approach may provide a practical strategy for reaching at-risk individuals who might otherwise remain unscreened. However, as no conventional cascade-screening comparator was included, the incremental benefit of the on-site component cannot be established and requires evaluation in comparative studies.
Related
- Profiling family resilience in chronic obstructive pulmonary disease: a network analysis approach to identifying intervention targets.
- Standardized and rapid protocol for drought tolerance screening at seedling stage in small grain cereals and their wild relatives
- Familial risks of hospital treated osteoporosis and fractures in first-, second- and third-degree relatives - A Swedish nationwide real-world family study
- Perceived Barriers and Facilitators to Colorectal Cancer Screening Among First-Degree Relatives in China: A Qualitative Interview Study.
- From caregiver burden to psychological resilience and positive emotional outcomes: the effectiveness of innovative psychiatric nursing intervention among family caregivers of patients with bipolar disorder.
BibTeX
@article{baran2026onsite,
title = {{“On-Site Family Screening” in Fabry Disease: An Innovative Model for Identifying At-Risk Relatives}},
author = {Erdem Baran and Gizem Kök and Hüseyin Onay},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207813},
url = {https://www.mdpi.com/2077-0383/15/20/7813},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - “On-Site Family Screening” in Fabry Disease: An Innovative Model for Identifying At-Risk Relatives
AU - Erdem Baran
AU - Gizem Kök
AU - Hüseyin Onay
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207813
UR - https://www.mdpi.com/2077-0383/15/20/7813
AB - Background: Fabry disease remains underdiagnosed despite the availability of effective therapies. Although cascade screening is recommended for identifying at-risk relatives, its implementation is often limited by practical and accessibility barriers, resulting in missed or delayed diagnoses. On-Site Family Screening (OSFS) was developed to overcome barriers to conventional cascade screening and improve the identification of previously undiagnosed relatives with Fabry disease. Therefore, this study aimed to implement and evaluate the diagnostic impact of an On-Site Family Screening approach for identifying previously undiagnosed individuals with Fabry disease within an extended family. Methods: Following the identification of the index case, at-risk relatives were systematically evaluated through on-site visits at their place of residence. Pedigree analysis was used to identify individuals at risk. Written informed consent was obtained from all participants prior to genetic testing, and molecular analysis of the GLA gene was performed. Of all at-risk relatives identified through pedigree analysis, ten at-risk individuals declined participation for personal reasons and were excluded from the analysis. Results: A total of 56 individuals were screened. Seventeen previously undiagnosed individuals with Fabry disease were identified, including 10 males and 7 females, corresponding to a diagnostic yield of 30.4%. The mean age at diagnosis was 22.94 years, with an age range from 45 days to 55 years. Notably, two affected male infants aged 45 and 60 days were detected before the development of overt disease manifestations. All affected individuals carried the same pathogenic GLA variant, consistent with familial X-linked inheritance. Conclusions: In this single extended pedigree, on-site family screening was feasible and facilitated the identification of previously undiagnosed relatives, including individuals at very young and presymptomatic stages. This approach may provide a practical strategy for reaching at-risk individuals who might otherwise remain unscreened. However, as no conventional cascade-screening comparator was included, the incremental benefit of the on-site component cannot be established and requires evaluation in comparative studies.
SN - 2077-0383
ER -